Neurotech International Ltd
Company Profile
Business description
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
Contact
55 Collins Street
Suite 102, Level 1
MelbourneVIC3000
AUST: +61 394983132
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
18
Stocks News & Analysis
stocks
Unwarranted drop in ASX share
stocks
After earnings, is Disney stock a buy, a sell, or fairly valued? -
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,281.80 | 97.30 | 1.06% |
| CAC 40 | 8,342.80 | 14.92 | 0.18% |
| DAX 40 | 24,977.98 | 9.87 | -0.04% |
| Dow JONES (US) | 50,422.64 | 234.50 | 0.47% |
| FTSE 100 | 10,461.23 | 107.39 | 1.04% |
| HKSE | 27,266.38 | 83.23 | 0.31% |
| NASDAQ | 23,222.15 | 119.67 | 0.52% |
| Nikkei 225 | 57,650.54 | 1,286.60 | 2.28% |
| NZX 50 Index | 13,507.28 | 60.91 | 0.45% |
| S&P 500 | 6,977.15 | 35.34 | 0.51% |
| S&P/ASX 200 | 9,014.80 | 98.80 | 1.11% |
| SSE Composite Index | 4,131.98 | 3.61 | 0.09% |